肺癌患者血清EGFR突变诊断实验的Meta分析  

Diagnostic Value of Serum from Lung Cancer Patient in Detection of Epidermal Growth Factor Receptor Mutation:A Meta Analysis

作　　者：张学德[1] 李维[1] 刘晓丽[1] 张玉萍[1] 侯彦丽[1] 牛泽群[1] 杨拴盈[1] 

机构地区：[1]西安交通大学第二附属医院呼吸科,西安710004

出　　处：《肿瘤防治研究》2014年第5期409-412,共4页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金资助项目(81172234)

摘　　要：目的评价肺癌患者血清EGFR突变诊断试验的准确性。方法收集关于肺癌患者血清与肺癌组织表皮生长因子受体(EGFR)突变检测相关研究的文献,并进行Meta分析,绘制SROC曲线。结果共纳入9篇文献,包括555例研究对象,合并敏感度为0.65,合并特异性为0.92,合并阳性似然比为8.29,合并阴性似然比为0.37,SROC曲线下面积0.94。结论肺癌患者血清与肿瘤组织的EGFR突变具有较高的一致性,利用外周血进行EGFR突变检测是一种可行办法。Objective To evaluate the diagnostic accuracy of serum from lung cancer patients in detection of epidermal growth factor receptor mutation. Methods Literatures on detecting epidermal growth factor receptor(EGFR) mutation in serum and tissue from patients with lung cancer were collected for meta-analysis and SROC curve. Results Nine literatures including 555 cases were involved. Meta-analyses showed that sensitivity, specificity, positive likelihood ratio, negative likelihood ratio of detecting EGFR mutation in serum compared with tissue were 0.65, 0.92, 7.85 and 0.37 respectively and the area under the SROC curve(AUC) was 0.94. Conclusion The detection of EGFR mutation is highly consistent in tissues and plasma DNA samples from lung cancer patients. The detection in plasma may serve as a feasible screening method for detecting EGFR mutations.

关 键 词：肺癌 表皮生长因子受体 诊断试验 系统评价 META分析 

分 类 号：R734.2[医药卫生—肿瘤]